EUCTR2010-022034-88-DK进行中（未招募）不适用
Evaluation of the optimal dose of prophylactic anticoagulation with low- molecular- weight heparin administered subcutaneously to critically ill patients – part 2 - LMWH prophylaxis for ICU patients
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients admitted to the intensive care unit with stays in the ICU> 24 hours, age> 18 years, weight between 50 and 90 kg will be included in the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with planned or emergency surgery within the study period, pregnant women, patients with heparin-induced thrombocytopenia or uncontrolled bleeding and patients with acute renal failure requiring CVVHDF therapy will be excluded.
研究者
相似试验
进行中（未招募）
1 期
Evaluation of the optimal dose of prophylactic anticoagulation with low-molecular-weight heparine administered subcutaneously to critically ill patients - low-molecular-weight heparin in critically ill patientsEUCTR2005-002381-10-DKDept anaesthesiology and intensive care80
已完成
2 期
Determination of optimal prophylactic dose of magnesium sulfate for prevention of atrial fibrillation after CABG surgeryAtrial fibrillation.Atrial fibrillation and flutterIRCT201211124365N15Vice chancellor for research of Mazandaran University of Medical Sciences120
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsEUCTR2011-001292-39-HUInstitut de Recherches Internationales Servier90
进行中（未招募）
不适用
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-SEInstitut de Recherches Internationales Servier90
进行中（未招募）
1 期
Determination of the efficacious and safe dose of ivabradine in paediatric patients with dilated cardiomyopathy and symptomatic chronic heart failure aged from 6 months to less than 18 yearsPaediatric dilated cardiomyopathy and symptomatic chronic heart failureMedDRA version: 14.1Level: LLTClassification code 10008908Term: Chronic heart failureSystem Organ Class: 10007541 - Cardiac disordersEUCTR2011-001292-39-ESab Servier116